MA48462A - Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation - Google Patents

Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation

Info

Publication number: MA48462A
Authority: MA; Morocco
Prior art keywords: methods; rankl antibodies; human; human anti; rankl
Prior art date: 2017-04-28

Application number

MA048462A

Other languages

English (en)

Other versions

MA48462B1 (fr

Inventor

Stephen Robert Brych

Jaymille Fallon

Pavan K Ghattyvenkatakrishna

Monica Michelle Goss

Jian Hua Gu

Lyanne M Wong

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-28

Filing date

2018-04-27

Publication date

2020-03-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62165668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA48462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-04-27 Application filed by Amgen Inc filed Critical Amgen Inc

2020-03-04 Publication of MA48462A publication Critical patent/MA48462A/fr

2024-05-31 Publication of MA48462B1 publication Critical patent/MA48462B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Microbiology (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

MA48462A 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation MA48462B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762492056P	2017-04-28	2017-04-28
PCT/US2018/029728 WO2018200918A1 (fr)	2017-04-28	2018-04-27	Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation

Publications (2)

Publication Number	Publication Date
MA48462A true MA48462A (fr)	2020-03-04
MA48462B1 MA48462B1 (fr)	2024-05-31

Family

ID=62165668

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA62173A MA62173B1 (fr)	2017-04-28	2018-04-27	Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation
MA48462A MA48462B1 (fr)	2017-04-28	2018-04-27	Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA62173A MA62173B1 (fr)	2017-04-28	2018-04-27	Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation

Country Status (37)

Country	Link
US (3)	US11192952B2 (fr)
EP (3)	EP3615066B1 (fr)
JP (4)	JP7190822B2 (fr)
KR (2)	KR20240110083A (fr)
CN (2)	CN110621342B (fr)
AR (1)	AR111497A1 (fr)
AU (2)	AU2018260750B2 (fr)
BR (1)	BR112019022188A2 (fr)
CA (1)	CA3054165A1 (fr)
CL (3)	CL2019003032A1 (fr)
CO (1)	CO2019011463A2 (fr)
CR (2)	CR20190538A (fr)
DK (2)	DK3615066T5 (fr)
EA (1)	EA201992570A1 (fr)
ES (2)	ES2997833T3 (fr)
FI (2)	FI3615066T3 (fr)
HR (2)	HRP20240167T1 (fr)
HU (2)	HUE069382T2 (fr)
IL (2)	IL293127B2 (fr)
JO (2)	JOP20190255B1 (fr)
LT (2)	LT3615066T (fr)
MA (2)	MA62173B1 (fr)
MX (1)	MX2023013460A (fr)
MY (1)	MY202479A (fr)
PE (2)	PE20251534A1 (fr)
PH (1)	PH12019502444A1 (fr)
PL (2)	PL3615066T3 (fr)
PT (2)	PT4190355T (fr)
RS (2)	RS65299B1 (fr)
SG (1)	SG11201909998TA (fr)
SI (2)	SI3615066T1 (fr)
SM (2)	SMT202400491T1 (fr)
TN (2)	TN2019000297A1 (fr)
TW (2)	TWI903512B (fr)
UY (2)	UY37707A (fr)
WO (1)	WO2018200918A1 (fr)
ZA (1)	ZA202205141B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3615066T3 (pl)	2017-04-28	2024-04-29	Amgen Inc.	Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
MA48461A (fr) *	2017-04-28	2020-03-04	Amgen Inc	Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
US20220008536A1 (en) *	2018-11-16	2022-01-13	Samsung Bioepis Co., Ltd.	Stable liquid composition comprising protein
CN109374779A (zh) *	2018-12-17	2019-02-22	杭州奕安济世生物药业有限公司	一种蔗糖含量的快速检测方法
PE20212185A1 (es)	2019-02-18	2021-11-11	Lilly Co Eli	Formulacion de anticuerpos terapeuticos
JP2022548950A (ja) *	2019-09-19	2022-11-22	イノベントバイオロジクス（スーチョウ）カンパニー，リミティド	抗ｐｃｓｋ９抗体を利用したコレステロール関連疾患の予防または治療方法
CN111704670B (zh) *	2020-08-18	2020-11-03	迈威(上海)生物科技股份有限公司	重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法
CA3197104A1 (fr) *	2020-11-11	2022-05-19	Hq Han	Antagonistes bifonctionnels de l'activine/tgf-beta et rankl et leurs utilisations
EP4337257A1 (fr) *	2021-05-12	2024-03-20	AnaptysBio, Inc.	Composition d'anticorps
US20240254245A1 (en) *	2021-05-12	2024-08-01	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
PE20240650A1 (es)	2021-08-12	2024-04-04	Amgen Inc	Formulaciones de anticuerpos
WO2023092177A1 (fr) *	2021-11-23	2023-06-01	Adalta Limited	Molécules de liaison rank -l
WO2023179791A1 (fr) *	2022-03-24	2023-09-28	Angitia Biomedicines Limited	Traitement de troubles musculo-squelettiques
AU2023347288A1 (en)	2022-09-23	2025-03-13	The University Of North Carolina At Chapel Hill	Methods and compositions for the treatment of melanoma
TW202434288A (zh) *	2022-11-16	2024-09-01	大陸商蘇州盛迪亞生物醫藥有限公司	一種含抗ｒａｎｋｌ－ｎｇｆ雙特異性抗體的醫藥組成物
JP2026507289A (ja) *	2023-03-03	2026-02-27	アルボテック・エイチエフ	デノスマブ製剤
CN121752600A (zh) *	2023-08-17	2026-03-27	中国抗体制药有限公司	靶向rankl和硬骨素的抗体及其用途
AU2024390979A1 (en) *	2023-12-01	2026-06-25	Samsung Bioepis Co., Ltd.	STABLE BUFFER-FREE LIQUID FORMULATION OF ANTI-IL-4Rα ANTIBODY

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR201809678T4 (tr)	2001-06-26	2018-07-23	Amgen Fremont Inc	Opgl ye karşi antikorlar.
AR056806A1 (es)	2005-11-14	2007-10-24	Amgen Inc	Moleculas quimericas de anticuerpo rankl- pth/ pthrp
EP2129401B8 (fr) *	2006-12-21	2020-01-15	Amgen Inc.	Formulations tamponnées stables contenant des polypeptides
AU2008269086B2 (en)	2007-06-25	2014-06-12	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
EP2249801A2 (fr) *	2008-02-07	2010-11-17	Amgen Inc.	Compositions protéiniques stabilisées
AR073072A1 (es)	2008-08-19	2010-10-13	Regeneron Pharma	Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
EP2684570A1 (fr)	2008-09-10	2014-01-15	F. Hoffmann-La Roche AG	Compositions et procédés permettant d'éviter la dégradation oxydative des protéines
US9265834B2 (en) *	2009-03-05	2016-02-23	Ablynx N.V.	Stable formulations of polypeptides and uses thereof
RU2565809C2 (ru)	2009-03-19	2015-10-20	Чугаи Сейяку Кабусики Кайся	Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
RU2600847C2 (ru)	2010-05-10	2016-10-27	Интас Биофармасьютикалс Лимитед	Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
EP2433644A1 (fr)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Traitement du cancer du sein
BR112013025845A2 (pt) *	2011-04-07	2018-09-04	Glaxosmithkline Llc	formulações com viscosidade reduzida
JP6176849B2 (ja)	2011-07-19	2017-08-09	中外製薬株式会社	アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AU2012328524B2 (en)	2011-10-28	2017-05-18	Excelse Bio, Inc.	Protein formulations containing amino acids
TWI679019B (zh)	2013-04-29	2019-12-11	法商賽諾菲公司	抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103965357B (zh)	2013-12-31	2016-08-17	嘉和生物药业有限公司	一种抗人rankl抗体
WO2015121318A1 (fr)	2014-02-12	2015-08-20	Sanofi	Formulations de polyglutamate/anticorps bispécifique anti-il-4/anti-il-13
WO2015134406A1 (fr) *	2014-03-03	2015-09-11	La Jolla Biologics, Inc.	Préparations aqueuses stables de protéine recombinée
US11173208B2 (en)	2014-05-07	2021-11-16	Takeda Gmbh	Liquid formulation comprising GM-CSF neutralizing compound
JP2018500380A (ja)	2014-12-31	2018-01-11	ノベルメドセラピューティクス，インコーポレーテッド	アグリコシル化治療用抗体の製剤
WO2016162819A1 (fr)	2015-04-07	2016-10-13	Lupin Limited	Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha
PL3615066T3 (pl)	2017-04-28	2024-04-29	Amgen Inc.	Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania

2018
- 2018-04-27 PL PL18724690.5T patent/PL3615066T3/pl unknown
- 2018-04-27 ES ES22206709T patent/ES2997833T3/es active Active
- 2018-04-27 BR BR112019022188-3A patent/BR112019022188A2/pt unknown
- 2018-04-27 PE PE2024002513A patent/PE20251534A1/es unknown
- 2018-04-27 EP EP18724690.5A patent/EP3615066B1/fr active Active
- 2018-04-27 PT PT222067092T patent/PT4190355T/pt unknown
- 2018-04-27 PL PL22206709.2T patent/PL4190355T3/pl unknown
- 2018-04-27 DK DK18724690.5T patent/DK3615066T5/da active
- 2018-04-27 KR KR1020247021825A patent/KR20240110083A/ko active Pending
- 2018-04-27 RS RS20240313A patent/RS65299B1/sr unknown
- 2018-04-27 CA CA3054165A patent/CA3054165A1/fr not_active Abandoned
- 2018-04-27 EP EP24194699.5A patent/EP4477667A3/fr active Pending
- 2018-04-27 UY UY0001037707A patent/UY37707A/es active IP Right Grant
- 2018-04-27 HU HUE22206709A patent/HUE069382T2/hu unknown
- 2018-04-27 CN CN201880028012.1A patent/CN110621342B/zh active Active
- 2018-04-27 CN CN202411089892.7A patent/CN118987200A/zh active Pending
- 2018-04-27 AU AU2018260750A patent/AU2018260750B2/en active Active
- 2018-04-27 LT LTEPPCT/US2018/029728T patent/LT3615066T/lt unknown
- 2018-04-27 FI FIEP18724690.5T patent/FI3615066T3/fi active
- 2018-04-27 SI SI201831067T patent/SI3615066T1/sl unknown
- 2018-04-27 TN TNP/2019/000297A patent/TN2019000297A1/en unknown
- 2018-04-27 EP EP22206709.2A patent/EP4190355B1/fr active Active
- 2018-04-27 SM SM20240491T patent/SMT202400491T1/it unknown
- 2018-04-27 JO JOJO/P/2019/0255A patent/JOP20190255B1/ar active
- 2018-04-27 TN TNP/2021/000055A patent/TN2021000055A1/en unknown
- 2018-04-27 SI SI201831178T patent/SI4190355T1/sl unknown
- 2018-04-27 MY MYPI2019006326A patent/MY202479A/en unknown
- 2018-04-27 LT LTEP22206709.2T patent/LT4190355T/lt unknown
- 2018-04-27 SM SM20240095T patent/SMT202400095T1/it unknown
- 2018-04-27 JP JP2018086261A patent/JP7190822B2/ja active Active
- 2018-04-27 AR ARP180101105A patent/AR111497A1/es not_active Application Discontinuation
- 2018-04-27 KR KR1020197034225A patent/KR102681171B1/ko active Active
- 2018-04-27 HU HUE18724690A patent/HUE065544T2/hu unknown
- 2018-04-27 EA EA201992570A patent/EA201992570A1/ru unknown
- 2018-04-27 RS RS20241343A patent/RS66284B1/sr unknown
- 2018-04-27 TW TW113118589A patent/TWI903512B/zh active
- 2018-04-27 TW TW107114370A patent/TWI839331B/zh active
- 2018-04-27 DK DK22206709.2T patent/DK4190355T3/da active
- 2018-04-27 PT PT187246905T patent/PT3615066T/pt unknown
- 2018-04-27 US US16/608,375 patent/US11192952B2/en active Active
- 2018-04-27 PE PE2019002120A patent/PE20200343A1/es unknown
- 2018-04-27 HR HRP20240167TT patent/HRP20240167T1/hr unknown
- 2018-04-27 HR HRP20241604TT patent/HRP20241604T1/hr unknown
- 2018-04-27 MA MA62173A patent/MA62173B1/fr unknown
- 2018-04-27 SG SG11201909998T patent/SG11201909998TA/en unknown
- 2018-04-27 CR CR20190538A patent/CR20190538A/es unknown
- 2018-04-27 ES ES18724690T patent/ES2973572T3/es active Active
- 2018-04-27 CR CR20250034A patent/CR20250034A/es unknown
- 2018-04-27 IL IL293127A patent/IL293127B2/en unknown
- 2018-04-27 FI FIEP22206709.2T patent/FI4190355T3/fi active
- 2018-04-27 UY UY0001040974A patent/UY40974A/es not_active Application Discontinuation
- 2018-04-27 WO PCT/US2018/029728 patent/WO2018200918A1/fr not_active Ceased
- 2018-04-27 MA MA48462A patent/MA48462B1/fr unknown
2019
- 2019-08-14 IL IL268704A patent/IL268704B/en unknown
- 2019-10-16 CO CO2019011463A patent/CO2019011463A2/es unknown
- 2019-10-21 MX MX2023013460A patent/MX2023013460A/es unknown
- 2019-10-23 CL CL2019003032A patent/CL2019003032A1/es unknown
- 2019-10-28 PH PH12019502444A patent/PH12019502444A1/en unknown
2020
- 2020-07-31 CL CL2020002012A patent/CL2020002012A1/es unknown
2021
- 2021-11-18 US US17/529,794 patent/US11873343B2/en active Active
2022
- 2022-01-14 JP JP2022004150A patent/JP7356525B2/ja active Active
- 2022-05-10 ZA ZA2022/05141A patent/ZA202205141B/en unknown
2023
- 2023-08-10 JP JP2023130715A patent/JP2023166396A/ja active Pending
- 2023-08-24 CL CL2023002505A patent/CL2023002505A1/es unknown
- 2023-12-11 US US18/535,068 patent/US20250326853A1/en active Pending
2024
- 2024-05-21 JO JOJO/P/2024/0115A patent/JOP20240115B1/ar active
2025
- 2025-02-17 JP JP2025023142A patent/JP7851438B2/ja active Active
- 2025-07-15 AU AU2025205470A patent/AU2025205470A1/en active Pending

Also Published As

Publication number	Publication date
MA48462B1 (fr)	2024-05-31
TWI839331B (zh)	2024-04-21
RS65299B1 (sr)	2024-04-30
EA201992570A1 (ru)	2020-03-20
PE20200343A1 (es)	2020-02-14
AU2018260750A1 (en)	2019-08-29
JOP20190255B1 (ar)	2024-12-22
SI3615066T1 (sl)	2024-04-30
JP7356525B2 (ja)	2023-10-04
EP3615066B1 (fr)	2023-12-27
SMT202400095T1 (it)	2024-05-14
US11192952B2 (en)	2021-12-07
CR20250034A (es)	2025-03-06
LT4190355T (lt)	2024-12-27
PT4190355T (pt)	2024-12-05
HUE065544T2 (hu)	2024-05-28
MX2023013460A (es)	2023-12-15
TN2019000297A1 (en)	2021-05-07
AR111497A1 (es)	2019-07-17
CL2023002505A1 (es)	2024-03-08
LT3615066T (lt)	2024-02-26
EP4477667A2 (fr)	2024-12-18
EP4190355B1 (fr)	2024-09-25
SI4190355T1 (sl)	2025-02-28
JP2022062059A (ja)	2022-04-19
US20200354463A1 (en)	2020-11-12
TW202435914A (zh)	2024-09-16
UY40974A (es)	2024-12-13
TN2021000055A1 (en)	2022-10-03
FI4190355T3 (fi)	2024-12-07
JP2023166396A (ja)	2023-11-21
US20220143181A1 (en)	2022-05-12
AU2025205470A1 (en)	2025-08-14
SG11201909998TA (en)	2019-11-28
WO2018200918A8 (fr)	2019-10-17
JP2018188430A (ja)	2018-11-29
PE20251534A1 (es)	2025-06-05
CL2019003032A1 (es)	2020-02-21
PH12019502444A1 (en)	2020-07-20
JOP20190255A1 (ar)	2019-10-27
MA62173B1 (fr)	2025-01-31
ES2997833T3 (en)	2025-02-18
IL268704B (en)	2022-06-01
CN118987200A (zh)	2024-11-22
CA3054165A1 (fr)	2018-11-01
EP4477667A3 (fr)	2025-05-07
IL268704A (en)	2019-10-31
IL293127A (en)	2022-07-01
PL4190355T3 (pl)	2025-02-10
CN110621342B (zh)	2024-08-02
US20250326853A1 (en)	2025-10-23
HRP20240167T1 (hr)	2024-04-26
IL293127B1 (en)	2024-02-01
JP2025093923A (ja)	2025-06-24
WO2018200918A1 (fr)	2018-11-01
RS66284B1 (sr)	2025-01-31
IL293127B2 (en)	2024-06-01
FI3615066T3 (fi)	2024-02-29
HRP20241604T1 (hr)	2025-01-31
UY37707A (es)	2018-10-31
HUE069382T2 (hu)	2025-03-28
CR20190538A (es)	2020-02-26
KR20240110083A (ko)	2024-07-12
JOP20240115B1 (ar)	2025-10-01
PT3615066T (pt)	2024-03-08
ES2973572T3 (es)	2024-06-20
JP7851438B2 (ja)	2026-04-24
DK4190355T3 (da)	2024-12-09
AU2018260750B2 (en)	2025-04-17
KR20190140464A (ko)	2019-12-19
SMT202400491T1 (it)	2025-01-14
DK3615066T5 (da)	2024-09-02
JP7190822B2 (ja)	2022-12-16
BR112019022188A2 (pt)	2020-05-12
CL2020002012A1 (es)	2020-10-16
MY202479A (en)	2024-04-30
TW201841654A (zh)	2018-12-01
DK3615066T3 (da)	2024-03-11
EP3615066A1 (fr)	2020-03-04
EP4190355A1 (fr)	2023-06-07
CO2019011463A2 (es)	2019-10-31
CN110621342A (zh)	2019-12-27
ZA202205141B (en)	2025-04-30
PL3615066T3 (pl)	2024-04-29
US11873343B2 (en)	2024-01-16
TWI903512B (zh)	2025-11-01
KR102681171B1 (ko)	2024-07-05

Publication	Publication Date	Title
FR24C1050I1 (fr)	2025-01-17	Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
EP3852805A4 (fr)	2022-06-15	Anticorps anti-lilrb2 et leurs méthodes d'utilisation
MA50957A (fr)	2020-10-14	Anticorps anti-tigit et leurs méthodes d'utilisation
MA45123A (fr)	2019-04-10	Anticorps anti-tim-3 et leurs méthodes d'utilisation
FR24C1044I2 (fr)	2025-05-23	Anticorps anti-c5 et leurs procédés d'utilisation
EP3917564A4 (fr)	2022-12-21	Anticorps anti-claudine 18 et leurs méthodes d'utilisation
EP3618871A4 (fr)	2021-01-06	Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3383430A4 (fr)	2019-12-18	Anticorps et leurs méthodes d'utilisation
EP3525583A4 (fr)	2020-06-10	Anticorps anti-c1s et leurs méthodes d'utilisation
EP3383431A4 (fr)	2019-08-28	Anticorps anti-gitr et leurs méthodes d'utilisation
MA42925A (fr)	2018-08-01	Anticorps anti-tigit et méthodes d'utilisation
MA71409A (fr)	2025-04-30	Constructions d'anticorps pour dll3 et cd3
MA50354A (fr)	2020-08-19	Anticorps ciblant le cd137 et leurs méthodes d'utilisation
EP3645742A4 (fr)	2021-07-14	Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA53355A (fr)	2022-03-16	Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA48579A (fr)	2020-03-18	Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EP3731867A4 (fr)	2022-04-06	Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3472316A4 (fr)	2020-01-08	Anticorps anti-c5 et leurs procédés d'utilisation
MA42447A (fr)	2018-05-23	Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3370770A4 (fr)	2019-06-12	Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA43658A (fr)	2018-11-28	Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation
MA42971A (fr)	2018-08-15	Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3684819A4 (fr)	2021-06-09	Anticorps anti-ykl40 et méthodes d'utilisation
EP3728323A4 (fr)	2022-01-26	Anticorps anti-fzd et méthodes d'utilisation
EP3491025A4 (fr)	2020-05-27	Anticorps fcrn et leurs procédés d'utilisation